Charles River Laboratories 4Q 2025 Results & 2026 Guidance February 18, 2026 Caution Concerning Forward-Looking Statements. This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "expect," "intend," "will," "may," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends o ...

You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Any forward-looking statement made by us is based only on information currently available to us and speaks only as of the date on which it is made. I ...

Financial Performance & Guidance - Charles River's 2Q25 revenue reached $1032.1 million, a 0.6% increase year-over-year, but experienced a 0.5% organic decline[12, 36] - Non-GAAP EPS for 2Q25 was $3.12, an 11.4% increase year-over-year[14, 36] - The company is raising its revenue guidance by +150 bps to a 1%-3% decrease organically and Non-GAAP EPS by +$0.55 at midpoint to $9.90-$10.30[15] - The updated 2025 organic revenue growth guidance is a decrease of 3.0%-1.0%[16, 37] - Free cash flow for 2Q25 was $169.3 million, with FY 2025 guidance at $430-$470 million[49] Segment Performance - DSA (Discovery and Safety Assessment) revenue for 2Q25 was $618.0 million, a 1.5% decrease year-over-year, with a 2.4% organic decline[17] - RMS (Research Models and Services) revenue for 2Q25 was $213.3 million, a 3.3% increase year-over-year, with a 2.3% organic increase[26] - Manufacturing Solutions revenue for 2Q25 was $200.8 million, a 4.4% increase year-over-year, with a 2.9% organic increase[30] Demand Trends & Outlook - DSA net book-to-bill dipped back below 1x in 2Q25, to 0.82x [10] - The company now expects DSA revenue to decline at a low- to mid-single-digit rate in 2025, an improvement from the prior outlook of a mid-single-digit decline[21] - NAMs (New Approach Methodologies) portfolio generates approximately $200 million in annual DSA revenue[24]